Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker

Bezu, 2015, Com-binatorial strategies for the induction of immunogenic cell death, Front. Immunol., 6, 187

Pentimalli, 2018, Cell death pathologies: Targeting death pathways and the immune system for cancer therapy, Genes Immun., 20, 539, 10.1038/s41435-018-0052-x

Galluzzi, 2017, Immunogenic cell death in cancer and infectious disease, Nat. Rev. Immunol., 17, 97, 10.1038/nri.2016.107

Pavlopoulou, 2019, In silico phylogenetic and structural analyses of plant endogenous danger signaling molecules upon stress, Oxid. Med. Cell Longev., 14, 8683054

Samara, 2017, Prothymosin alpha: An alarmin and more, Curr. Med. Chem., 24, 1747, 10.2174/0929867324666170518110033

Krysko, 2012, Immunogenic cell death and DAMPs in cancer therapy, Nat. Rev. Cancer, 12, 860, 10.1038/nrc3380

Adkins, 2017, Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells, Oncoimmunology, 6, e1311433, 10.1080/2162402X.2017.1311433

Anel, 2019, Immunogenic cell death and immunotherapy of multiple myeloma, Front. Cell Dev. Biol., 7, 50, 10.3389/fcell.2019.00050

Galluzzi, 2018, Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018, Cell Death Differ., 25, 486, 10.1038/s41418-017-0012-4

Poon, 2014, Apoptotic cell clearance: Basic biology and therapeutic potential, Nat. Rev. Immunol., 14, 166, 10.1038/nri3607

Yatim, 2015, RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8 + T cells, Science, 350, 328, 10.1126/science.aad0395

Krysko, 2010, Clearance of dead cells: Mechanisms, immune responses and implication in the development of diseases, Apoptosis, 15, 995, 10.1007/s10495-010-0524-6

Stuart, 2002, Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation, J. Immunol., 168, 1627, 10.4049/jimmunol.168.4.1627

Voll, 1997, Immunosuppressive effects of apoptotic cells, Nature, 390, 350, 10.1038/37022

Garg, 2010, Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation, Biochim. Biophys. Acta Rev. Cancer, 1805, 53, 10.1016/j.bbcan.2009.08.003

Obeid, 2007, Calreticulin exposure dictates the immunogenicity of cancer cell death, Nat. Med., 13, 54, 10.1038/nm1523

Galluzzi, 2020, Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors, Nat. Rev. Clin. Oncol., 17, 725, 10.1038/s41571-020-0413-z

Kroemer, 2022, Immunogenic cell stress and death, Nat. Immunol., 23, 487, 10.1038/s41590-022-01132-2

Bedognetti, 2019, Toward a comprehensive view of cancer immune responsiveness: A synopsis from the SITC workshop, J. Immunother. Cancer, 7, 167, 10.1186/s40425-019-0640-y

Fucikova, 2020, Detection of immunogenic cell death and its relevance for cancer therapy, Cell Death Dis., 11, 1013, 10.1038/s41419-020-03221-2

Fulda, 2004, Apoptosis signaling in tumor therapy, Ann. N. Y. Acad. Sci., 1028, 150, 10.1196/annals.1322.016

Fulda, 2006, Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy, Oncogene, 25, 4798, 10.1038/sj.onc.1209608

Walczak, 2000, The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems, Exp. Cell Res., 256, 58, 10.1006/excr.2000.4840

Saelens, 2004, Toxic proteins released from mitochondria in cell death, Oncogene, 23, 2861, 10.1038/sj.onc.1207523

Yatim, 2017, Dying cells actively regulate adaptive immune responses, Nat. Rev. Immunol., 17, 262, 10.1038/nri.2017.9

Albert, 1998, Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs, Nature, 392, 86, 10.1038/32183

Rawson, 2007, Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection, Nat. Med., 13, 1431, 10.1038/nm1679

Green, 2009, Immunogenic and tolerogenic cell death, Nat. Rev. Immunol., 9, 353, 10.1038/nri2545

Casares, 2005, Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death, J. Exp. Med., 202, 1691, 10.1084/jem.20050915

Gamrekelashvili, 2013, Peptidases released by necrotic cells control CD8+ T cell cross-priming, J. Clin. Investig., 123, 4755, 10.1172/JCI65698

Vercammen, 1998, Dual signaling of the Fas receptor: Initiation of both apoptotic and necrotic cell death pathways, J. Exp. Med., 188, 919, 10.1084/jem.188.5.919

Kaiser, 2013, Viral modulation of programmed necrosis, Curr. Opin. Virol., 3, 296, 10.1016/j.coviro.2013.05.019

Lamkanfi, 2016, Pyroptosis, Curr. Biol., 26, 568, 10.1016/j.cub.2016.02.019

Franchi, 2009, The inflammasome: A caspase-1 activation platform regulating im-mune responses and disease pathogenesis, Nat. Immunol., 10, 241, 10.1038/ni.1703

Liu, 2019, Neutrophil pyroptosis: New perspectives on sepsis, Cell Mol. Life Sci., 76, 2031, 10.1007/s00018-019-03060-1

Stockwell, 2017, Primer ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease, Cell, 171, 273, 10.1016/j.cell.2017.09.021

Fearnhead, 2017, How do we fit ferroptosis in the family of regulated cell death?, Cell Death Differ., 24, 1991, 10.1038/cdd.2017.149

Sun, 2020, The emerging role of ferroptosis in inflammation, Biomed. Pharmacother., 127, 110108, 10.1016/j.biopha.2020.110108

Peng, 2020, Involvement of regulated necrosis in blinding diseases: Focus on necroptosis and ferroptosis, Exp. Eye Res., 191, 107922, 10.1016/j.exer.2020.107922

David, 2009, Parthanatos, a messenger of death, Front. Biosci. Landmark, 14, 1116, 10.2741/3297

Robinson, 2019, Programmed necrotic cell death of macro-phages: Focus on pyroptosis, necroptosis, and parthanatos, Redox Biol., 26, 101239, 10.1016/j.redox.2019.101239

Kroemer, 2005, Classification of cell death: Recommendations of the Nomenclature Committee on Cell Death, Cell Death Differ., 12, 1463, 10.1038/sj.cdd.4401724

Yan, 2020, Multiple cell death modalities and their key features, World Acad. Sci. J., 2, 39

Tang, 2019, The molecular machinery of regulated cell death, Cell Res., 29, 347, 10.1038/s41422-019-0164-5

Yousefi, 2019, Untangling “NETosis” from NETs, Eur. J. Immunol., 49, 221, 10.1002/eji.201747053

Liu, 2015, Autosis and autophagic cell death: The dark side of autophagy, Cell Death Differ., 22, 367, 10.1038/cdd.2014.143

Vandenabeele, 2016, Immunogenic apoptotic cell death and anticancer immunity, Adv. Exp. Med. Biol., 930, 133, 10.1007/978-3-319-39406-0_6

Showalter, 2017, Cytokines in immunogenic cell death: Applications for cancer immunotherapy, Cytokine, 97, 123, 10.1016/j.cyto.2017.05.024

Yu, 2006, HMGB1 signals through Toll-like receptor (TLR) 4 and TLR2, Shock, 26, 174, 10.1097/01.shk.0000225404.51320.82

Zhou, 2019, Immunogenic cell death in cancer therapy: Present and emerging inducers, J. Cell. Mol. Med., 23, 4854, 10.1111/jcmm.14356

Wang, 2018, Immunogenic effects of chemotherapy-induced tumor cell death, Genes Dis., 5, 194, 10.1016/j.gendis.2018.05.003

Huang, 2018, Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy, Cancer Immunol. Immunother., 67, 551, 10.1007/s00262-017-2109-5

Suzuki, 2012, Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma, Cancer Res., 72, 3967, 10.1158/0008-5472.CAN-12-0851

Lämmer, F., Delbridge, C., Würstle, C., Neff, F., Meyer, B., Schlegel, J., Kessel, K.A., Schmid, T.E., Schilling, D., and Combs, S.E. (2019). Cytosolic Hsp70 as a biomarker to predict clinical outcome in patients with glioblastoma. PLoS ONE, 14.

Kasikova, 2020, Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death, Methods Enzymol., 632, 15, 10.1016/bs.mie.2019.05.025

Sukkurwala, 2014, Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set, Oncoimmunology, 3, e28473, 10.4161/onci.28473

Golden, 2015, Radiotherapy and immunogenic cell death, Semin. Radiat. Oncol., 25, 11, 10.1016/j.semradonc.2014.07.005

Golden, 2014, Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death, Oncoimmunology, 25, e28518, 10.4161/onci.28518

Golden, 2012, The convergence of radiation and immunogenic cell death signaling pathways, Front. Oncol., 2, 88, 10.3389/fonc.2012.00088

Fucikova, 2011, Human tumor cells killed by anthracyclines induce a tumor-specific immune response, Cancer Res., 71, 4821, 10.1158/0008-5472.CAN-11-0950

Tesniere, 2010, Immunogenic death of colon cancer cells treated with oxaliplatin, Oncogene, 29, 482, 10.1038/onc.2009.356

Gandolfi, 2017, The proteasome and proteasome inhibitors in multiple myeloma, Cancer Metastasis Rev., 36, 561, 10.1007/s10555-017-9707-8

Spisek, 2007, Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications, Blood, 109, 4839, 10.1182/blood-2006-10-054221

Chen, 2012, Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine, Cancer Immunol. Immunother., 61, 1989, 10.1007/s00262-012-1258-9

Mavragani, I.V., Nikitaki, Z., Kalospyros, S.A., and Georgakilas, A.G. (2019). Ionizing radiation and complex DNA damage: From pre-diction to detection challenges and biological significance. Cancers, 11.

Garg, 2013, ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death, Autophagy, 9, 1292, 10.4161/auto.25399

Garg, 2012, A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death, EMBO J., 31, 1062, 10.1038/emboj.2011.497

Bugaut, H., Bruchard, M., Berger, H., Derangère, V., Odoul, L., Euvrard, R., Ladoire, S., Chalmin, F., Végran, F., and Rébé, C. (2013). Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regu-latory T cells. PLoS ONE, 8.

Haritos, 1984, Prothymosin alpha: Isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus, Proc. Natl. Acad. Sci. USA, 81, 1008, 10.1073/pnas.81.4.1008

Manrow, 1991, Nuclear targeting of prothymosin alpha, J. Biol. Chem., 266, 3916, 10.1016/S0021-9258(19)67881-6

Rubtsov, 1997, Mutational analysis of human prothymosin α reveals a bipartite nuclear localization signal, FEBS Lett., 413, 135, 10.1016/S0014-5793(97)00824-7

Cordero, 2000, Fifteen years of prothymosin alpha: Contradictory past and new horizons, Peptides, 21, 1433, 10.1016/S0196-9781(00)00288-6

Samara, 2016, Prothymosin alpha and immune responses: Are we close to potential clinical ap-plications?, Vitam. Horm., 102, 179, 10.1016/bs.vh.2016.04.008

Karetsou, 1998, Prothymosin alpha modulates the interaction of histone H1 with chromatin, Nucleic Acids Res., 26, 3111, 10.1093/nar/26.13.3111

George, 2011, Prothymosin α is a component of a linker histone chaperone, FEBS Lett., 584, 2833, 10.1016/j.febslet.2010.04.065

Karetsou, 2002, Prothymosin α interacts with the CREB-binding protein and potentiates transcription, EMBO Rep., 3, 361, 10.1093/embo-reports/kvf071

Qi, 2010, Novel small molecules relieve prothymosin α-mediated inhibition of apoptosome formation by blocking its interaction with Apaf-1, Biochemistry, 49, 1923, 10.1021/bi9022329

Niture, 2010, Nrf2 signaling and cell survival, Toxicol. Appl. Pharmacol., 244, 37, 10.1016/j.taap.2009.06.009

Ntuli, M.T. (2015). HMGB1 in Cell Death. Cell Death-Autophagy, Apoptosis and Necrosis, IntechOpen.

Ozaki, 2002, HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter, J. Biol. Chem., 277, 7157, 10.1074/jbc.M110233200

Song, 2004, The DNA architectural protein HMGB1 facilitates RTA-mediated viral gene expression in gamma-2 herpesviruses, J. Virol., 78, 12940, 10.1128/JVI.78.23.12940-12950.2004

Liu, 2010, HMGB1: Roles in base excision repair and related function, Biochim. Biophys. Acta, 1799, 119, 10.1016/j.bbagrm.2009.11.008

Livesey, 2012, p53/HMGB1 complexes regulate autophagy and apoptosis, Cancer Res., 72, 1996, 10.1158/0008-5472.CAN-11-2291

Skopeliti, 2006, The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients, Cancer Immunol. Immunother., 55, 1247, 10.1007/s00262-005-0108-4

Skopeliti, 2009, Prothymosin alpha immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces den-dritic cell maturation and adopts a beta-sheet conformation in a sequence-specific manner, Mol. Immunol., 46, 784, 10.1016/j.molimm.2008.09.014

Pan, 1986, Human prothymosin α: Amino acid sequence and immunologic properties, Arch. Biochem. Biophys., 250, 197, 10.1016/0003-9861(86)90717-4

Baxevanis, 1990, Enhancement of human T lymphocyte function by prothymosin alpha: Increased production of interleukin-2 and expression of interleukin-2 receptors in normal human peripheral blood T lymphocytes, Immunopharmacol. Immunotoxicol., 12, 595, 10.3109/08923979009019679

Cordero, 1991, Prothymosin α enhances interleukin 2 receptor expression in normal human T-lymphocytes, Int. J. Immunopharmacol., 13, 1059, 10.1016/0192-0561(91)90156-2

Baxevanis, 1992, Prothymosin alpha enhances human and murine MHC class II surface antigen expression and messenger RNA accumulation, J. Immunol., 148, 1979, 10.4049/jimmunol.148.7.1979

Ioannou, K., Derhovanessian, E., Tsakiri, E., Samara, P., Kalbacher, H., Voelter, W., Trougakos, I.P., Pawelec, G., and Tsitsilonis, O.E. (2013). Prothymosin α and a prothymosin α-derived peptide enhance TH1-type immune responses against defined HER-2/neu epitopes. BMC Immunol., 14.

Samara, 2013, The C-terminal decapeptide of prothymosin α is responsible for its stimulatory effect on the functions of human neutrophils in vitro, Int. Immunopharmacol., 15, 50, 10.1016/j.intimp.2012.11.011

Birmpilis, A.I., Karachaliou, C.E., Samara, P., Ioannou, K., Selemenakis, P., Kostopoulos, I.V., Kavrochorianou, N., Kalbacher, H., Livaniou, E., and Haralambous, S. (2019). Antitumor reactive T-cell responses are enhanced in vivo by DAMP prothymosin alpha and its C-terminal decapeptide. Cancers, 11.

Mosoian, 2010, Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction, Proc. Natl. Acad. Sci. USA, 107, 10178, 10.1073/pnas.0914870107

Karachaliou, 2017, In vivo biodistribution and imaging studies with a 99mTc-radiolabeled derivative of the C-terminus of prothymosin alpha in mice bearing experimentally-induced inflammation, Eur. J. Pharm. Biopharm., 113, 188, 10.1016/j.ejpb.2016.12.028

Curtin, J.F., Liu, N., Candolfi, M., Xiong, W., Assi, H., Yagiz, K., Edwards, M.R., Michelsen, K.S., Kroeger, K.M., and Liu, C. (2009). HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med., 6.

Fan, 2007, Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: Role of HMGB1-TLR4 signaling, J. Immunol., 178, 6573, 10.4049/jimmunol.178.10.6573

Apetoh, 2007, Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nat. Med., 13, 1050, 10.1038/nm1622

Telusma, 2006, Dendritic cell activating peptides induce distinct cytokine profiles, Int. Immunol., 18, 1563, 10.1093/intimm/dxl089

Saenz, 2010, HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen, Vaccine, 28, 7556, 10.1016/j.vaccine.2010.08.054

LeBlanc, 2014, An immunogenic peptide in the A-box of HMGB1 protein reverses apoptosis-induced tolerance through RAGE receptor, J. Biol. Chem., 289, 7777, 10.1074/jbc.M113.541474

Evstafieva, 2003, Apoptosis-related fragmentation, translocation, and properties of human prothymosin alpha, Exp. Cell Res., 284, 211, 10.1016/S0014-4827(02)00047-2

Samara, 2017, A fragment of the alarmin prothymosin α as a novel biomarker in murine models of bacteria-induced sepsis, Oncotarget, 8, 48635, 10.18632/oncotarget.18149

Samara, 2013, Development of an ELISA for the quantification of the C-terminal decapeptide prothymosin α(100–109) in sera of mice infected with bacteria, J. Immunol. Methods, 395, 54, 10.1016/j.jim.2013.06.011

Karachaliou, 2019, Development of a specific IgY-based ELISA for prothymosin alpha, a bioactive polypeptide with diagnostic and therapeutic potential, Heliyon, 5, e02616, 10.1016/j.heliyon.2019.e02616

Baxevanis, 1994, Induction of lymphokine-activated killer activity in mice by prothymosin alpha, Cancer Immunol. Immunother., 38, 281, 10.1007/BF01533521

Eggleton, 2016, Calreticulin, a therapeutic target?, Expert Opin. Ther. Targets, 20, 1137, 10.1517/14728222.2016.1164695

Rapaport, 1983, Growth inhibition of human tumor cells in soft-agar cultures by treatment with low levels of adenosine 5′-triphosphate, Cancer Res., 43, 4402

Beijer, S., Van Rossum, E., Hupperets, P.S., Spreeuwenberg, C., van den Beuken, M., Winkens, R.A., Ars, L., van den Borne, B.E., de Graeff, A., and Dagnelie, P.C. (2007). Application of adenosine 5′-triphosphate (ATP) infusions in palliative home care: Design of a randomized clinical trial. BMC Public Health, 7.

Jiang, 2015, ATP, a double-edged sword in cancer, Oncoscience, 2, 673, 10.18632/oncoscience.230

Andersson, 2011, HMGB1 is a therapeutic target for sterile inflammation and infection, Annu. Rev. Immunol., 29, 139, 10.1146/annurev-immunol-030409-101323

Vulczak, A., Catalão, C.H.R., De Freitas, L.A.P., and Rocha, M.J.A. (2019). HSP-Target of therapeutic agents in sepsis treatment. Int. J. Mol. Sci., 20.

Venereau, 2016, HMGB1 as biomarker and drug target, Pharmacol. Res., 111, 534, 10.1016/j.phrs.2016.06.031